30 results
8-K
EX-99.1
NRBO
NeuroBo Pharmaceuticals Inc
9 May 24
NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results
8:05am
are expected to be available in the fourth quarter of 2024.
First Quarter Financial and Operating Results
Research and Development (R&D) Expenses were … , the $4.3 million increase in R&D expenses was primarily attributable to (i) $3.9 million in higher expenditures for investigational drug manufacturing
8-K
EX-99.1
fwe3n
28 Mar 24
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
8:01am
8-K
EX-99.1
3v7bzlg52lc3rmmg7tr
13 Nov 23
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
qde66av5kboni0ggib0j
6 Nov 23
Departure of Directors or Certain Officers
8:20am
8-K
EX-99.1
jlljringpsf9d1
22 Sep 23
Regulation FD Disclosure
8:03am
8-K
EX-99.1
om0l0
9 Aug 23
NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:20pm
8-K
EX-99.1
55z71f
30 Mar 23
NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results
4:47pm
8-K
EX-99.1
9aotw6 j959
15 Sep 22
Other Events
8:43am
8-K
EX-10.1
t0wnxs5go 7finqijx
14 Sep 22
Entry into a Material Definitive Agreement
5:11pm
8-K
EX-99.1
qjyvlpvl 99f1iq6k
1 Apr 22
NeuroBo Pharmaceuticals Reports Full Year 2021 Financial Results
8:18am
8-K
EX-99.1
7ozcgc43wxn
15 Nov 21
NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results
8:18am
8-K
EX-99.1
2mdlh21
16 Aug 21
NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results
8:13am